Online citations, reference lists, and bibliographies.
← Back to Search

A Systematic Review And Meta-analysis Of Surgical Treatments For Malignant Pleural Mesothelioma.

C. Cao, D. Tian, John Park, J. Allan, Kristopher A. Pataky, T. Yan
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Malignant pleural mesothelioma (MPM) is an aggressive disease of the pleural lining with a dismal prognosis. Surgical treatments of MPM with a curative intent include extrapleural pneumonectomy and extended pleurectomy/decortication (P/D). This meta-analysis aimed to compare the perioperative and long-term outcomes of EPP and extended P/D for selected surgical candidates. METHODS A systematic review of the literature was performed on six electronic databases to identify all relevant data on comparative outcomes of extended P/D and EPP in a multimodality setting. Endpoints included perioperative mortality and morbidity, as well as long-term overall survival. RESULTS Seven relevant studies with comparative data on EPP (n=632) versus extended P/D (n=513) were identified from the current literature. Comparison of these two groups demonstrated significantly lower perioperative mortality (2.9% vs. 6.8%, p=0.02) and morbidity (27.9% vs. 62.0%, p<0.0001) for patients who underwent extended P/D compared to EPP. Median overall survival ranged between 13-29 months for extended P/D and 12-22 months for EPP, with a trend favouring extended P/D. CONCLUSIONS Although it must be emphasized that patient selection and treatment strategies differ between EPP and extended P/D, a number of comparative studies have recently been conducted to compare these two surgical techniques for patients with resectable MPM. The present study indicated that selected patients who underwent extended P/D had lower perioperative morbidity and mortality with similar, if not superior, long-term survival compared to EPP, in the context of multi-modality therapy. This may represent an important paradigm shift in the surgical management of MPM.
This paper references
10.1016/J.EJCTS.2006.11.046
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
M. Lucchi (2007)
10.1093/ejcts/ezr192
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
A. Nakas (2012)
10.3978/j.issn.2225-319X.2012.11.07
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1510/ICVTS.2007.166322
Radical surgery for malignant pleural mesothelioma: results and prognosis.
M. Okada (2008)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1097/JTO.0B013E318156AF3B
Mesothelioma: benefit from surgical resection is questionable.
T. Treasure (2007)
10.1016/j.lungcan.2013.04.024
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
C. Cao (2013)
10.1016/j.ejcts.2009.08.016
Surgery for mesothelioma: MARS landing and future missions.
T. Treasure (2010)
10.1097/JTO.0b013e3181b7d470
The Mars trial: resolution of the surgical controversies in mesothelioma?
Valerie Rusch (2009)
10.1002/SIM.1186
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
Landau Page 19 of 25 Ac ce pt ed M an us cr ip t 19
T Treasure (2011)
10.1016/j.lungcan.2011.12.009
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.3978/j.issn.2225-319X.2012.11.06
Video-assisted thoracoscopic extrapleural pneumonectomy for malignant pleural mesothelioma.
T. Demmy (2012)
10.1177/0218492312454017
Changes in lung function after surgery for mesothelioma
T. Ploenes (2013)
10.1016/j.hlc.2010.11.045
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
10.1053/j.semtcvs.2009.07.007
Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication.
A. Wolf (2009)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1016/j.jtcvs.2008.07.055
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
L. Zellos (2009)
A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma.
Valerie Rusch (2007)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1245/s10434-011-1728-x
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Mbbs Christopher Cao BSc (2011)
10.1097/JTO.0b013e3181ae26ae
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
10.3978/j.issn.2072-1439.2013.07.40
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
M. A. Bedirhan (2013)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.3978/j.issn.2225-319X.2012.11.13
Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.
V. Rusch (2012)



This paper is referenced by
10.5090/kjtcs.2018.51.1.35
Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery
Bub-Se Na (2018)
10.1093/ejcts/ezv403
The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication.
A. Sharkey (2016)
10.1016/j.jtho.2018.10.005
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery
Edward J A Harris (2019)
10.1101/2020.05.13.20087189
Trimodality Treatment in Malignant Pleural Mesothelioma: An Ordeal or The Real Deal?
Naveen Mummudi (2020)
10.1093/ejcts/ezw215
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
Maurizio Infante (2016)
10.21037/jtd.2018.01.171
Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?
S. Boeluekbas (2018)
10.1016/J.JTCVS.2019.07.073
Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.
I. Opitz (2019)
10.3892/ol.2019.9979
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.
Yuichiro Kai (2019)
Using Next-Generation Sequencing To Interrogate Circulating Tumour DNA In Thoracic Malignancies And As A Diagnostic Tool
Luke Martinson (2019)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1038/bjc.2014.478
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
10.13032/TJOP.2052-5931.100120
The Role of Surgery in Malignant Pleural Mesothelioma
Levon Toufektzian (2015)
10.1080/17476348.2019.1678386
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
Giovanni Luca Ceresoli (2019)
10.1007/s12055-017-0606-y
Surgery for mesothelioma: the evidence base and a pragmatic approach to surgical treatment
Vasudev Baburaya Pai (2017)
10.1016/j.athoracsur.2014.12.077
Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?
C. Munck (2015)
10.1093/icvts/ivw422
Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients.
Arthur Kostron (2017)
A new signal transducer and activator of transcription 3 inhibitor, BBI608, in malignant mesothelioma cell lines
T. Yamagishi (2019)
10.1080/0284186X.2016.1234066
Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study
Angela Botticella (2016)
10.1016/j.prro.2015.07.010
Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma.
Amar U. Kishan (2015)
10.1016/j.lungcan.2015.05.014
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
10.1016/j.jtho.2018.08.001
Surgery in Malignant Pleural Mesothelioma
R. Bueno (2018)
10.1007/978-3-319-28761-4_21
Modern Surgical Techniques in Malignant Pleural Mesothelioma
Yusuf Kahya (2016)
10.18632/oncotarget.22062
Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis
Z. Zhao (2017)
10.1055/s-0039-1693406
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
10.1016/j.athoracsur.2014.09.056
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
E. Taioli (2015)
10.1007/s12254-014-0166-4
A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
Bahil Ghanim (2014)
10.1016/j.resinv.2017.12.002
Current surgical treatment of malignant pleural mesothelioma.
Koji Chihara (2018)
10.1055/s-0039-1695784
Surgical Outcomes and Risk Analysis of Primary Pulmonary Sarcoma.
Yoshito Yamada (2019)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.2217/fon.14.256
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience.
M. Migliore (2015)
10.1016/j.jtho.2017.02.026
Improved Outcomes with Modern Lung‐Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma
F. Shaikh (2017)
10.1007/s00066-017-1108-y
Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation?
Angela Botticella (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar